STIM selected as UK distributor for Benchmark lice treatment

Aquaculture biotechnology company Benchmark Animal Health has entered an exclusive UK distribution agreement with STIM Scotland Ltd for the lice treatment Salmosan^® Vet.

The agreement was signed on 28 March, and will take immediate effect with the stock now transferred to STIM’s Glasgow warehouse ahead of distribution.

Salmosan^® Vet is a market leading azamethiphos treatment for sea lice and one product within Benchmark’s Animal Health portfolio. The product is used throughout the global salmon industry for the control of pre-adult to adult stages of sea lice.

Benchmark said it is “…well recognised as a reliable, gentle and effective treatment option.”

The agreement will increase the technical support available for UK customers, with both Benchmark and STIM on hand to support their sea lice management.

Benchmark said: “STIM Scotland Ltd are professional distributors with a well-established and trusted network of delivery, which will ensure customers can access secure and consistent supply.”

Announcing the agreement, John Marshall, Head of Benchmark Animal Health, said: “At Benchmark, we are committed to helping customers manage the ongoing challenge of sea lice. Our exclusive agreement with STIM Scotland offers us the opportunity to further support our customers in their use of Salmosan^® Vet. I am confident this will have a positive impact on our customer’s operations”.

Campbell Morrison, Key Account Manager at STIM Scotland Ltd, added: “In the UK, as well as in Norway and Chile, STIM strives to supply a complete range of the most important fish health products available. Salmosan^® Vet is certainly one of those and we are pleased to add the product to our growing product catalogue.”

Managing sea lice carries an annual cost of approximately £40m in Scotland alone.

Benchmark Animal Health is the Marketing Authorisation holder for Salmosan^® Vet in the UK and will remain so after the agreement.